CRL

Charles River Laboratories International, Inc.

$182.07 +0.75%

Recent alerts on CRL

All signals →

News Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing

News Charles River (CRL) Q2 EPS Jumps 11%

News Wall Street Pulls Back After Early Gains As Tariff Uncertainties Persist: What's Driving Markets Monday?

News Trump 16-17 Vs. Trump 24 -25: The Stock Market 'Math' Still Looks Complicated

News Charles River's (CRL) RMS Growth Aids Amid FX Headwind

News Demystifying Charles River: Insights From 4 Analyst Reviews

News These Nike Analysts Are No Longer Bullish; Here Are Top 5 Downgrades For Friday

News Charles River (CRL) Inks CDMO Deal With Gates Institutes

News Charles River (CRL) Advances in T-Cell Therapy With New Alliance

News Charles River (CRL) Partners to Reduce Animal Research Usage

News Charles River (CRL) Launches Viral Vector Tech Transfer Program

News Charles River (CRL) Banks on RMS Growth Amid Competition

News Most healthcare companies report higher Y/Y EPS in strong earnings week

News Charles River reaffirms 2026 EPS $10.80-$11.30, targets ~120-150 bps margin expansion as divestitures close

News Charles River Laboratories Non-GAAP EPS of $2.06 beats by $0.12, revenue of $995.8M beats by $18.36M

SEC filing CRL Reports $995.8M Revenue, $(0.30) GAAP EPS, $2.06 Non-GAAP EPS, Reaffirms 2026 Guidance, Repurchases $200M Stock, Divests CDMO and Cell Solutions

News Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and CVS Health in focus

Insider trade Purchase by Joseph W Laplume (EVP, Corp Strategy & Develop)

News Notable healthcare headlines for the week: Viatris, Novo Nordisk, and Gilead Sciences in focus

News Charles River Labs Breaks The Mold, Announces Bold Divestiture Plans

SEC filing CRL Appoints Glenn Coleman CFO, $800K Salary, $1.875M Cash, $3.5M Equity, $3M Equity, 85% Bonus Target

News Charles River projects up to 9% EPS growth in 2026 as new CEO, acquisitions, and cost savings drive margin expansion

SEC filing CRL Reports $994.2M Q4 Rev, $(5.62) GAAP EPS, $2.39 Non-GAAP EPS, $4.02B FY Rev, $10.28 Non-GAAP EPS, $50B 2026 Guidance

Insider trade Sale by Joseph W Laplume

Short volume Short volume 63% of volume (3.5σ)

Get push alerts for CRL

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS

Download for iOS